PhD, Laboratory Director, Reprogenetics
Current methods for the detection of aneuploid embryos have proven highly successful, but are they with us to stay or will they be superseded by newer techniques? This lecture will examine the possibilities afforded by novel technologies and consider whether technical advances might change the face of PGS in the near future.
Dagan Wells has been actively involved in preimplantation genetic diagnosis (PGD) and the study of human gametes and embryos for two decades, conducting his first PGD cases in 1992. After a time designing novel molecular tests at the UCL Centre for PGD in London, Dagan moved to the United States and joined Reprogenetics, one of the largest providers of PGD services in the USA. In 2003 he initiated Reprogenetics’ highly successful single gene PGD program, testing embryos for numerous serious inherited conditions. Dagan later joined the faculty of Yale University Medical School, where he spent four years as an Assistant Professor, before returning to the UK in October 2007.
His research group is now located in the Nuffield Department of Obstetrics and Gynaecology at the University of Oxford. Dagan’s work has led to the publication of more than 120 peer-review publications and book chapters and has been recognized with the award of several prizes, including the ASRM General Program Prize, the ESHRE Basic Science Prize and the Society for Assisted Reproductive Technologies Prize. He is a Fellow of the Royal College of Pathologists and currently serves on the Editorial Boards of Molecular Human Reproduction, Reproductive Biomedicine Online and Prenatal Diagnosis. Dagan also directs Reprogenetics-UK, an independent laboratory offering state-of-the-art PGD services to IVF clinics throughout the UK and internationally.